Sunday, March 26, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Health Security

Federal Select Agent Program Clarifies Requirements for Botulinum Neurotoxin Gene Constructs

by Global Biodefense Staff
May 4, 2022
Federal Select Agent Program Clarifies Requirements for Botulinum Neurotoxin Gene Constructs

Emerito Rodriguez, medical technologist/biosafety officer, conducts the test in BSL3 and shows results on computer screen. Rodriguez batches samples for testing on a testing plate. Photo credit: Christina Westover

The Federal Select Agent Program, part of the Centers for Disease Control and Prevention Division of Select Agents and Toxins, recently posted an updated regulatory interpretation regarding constructs of botulinum neurotoxin genes in response to a stakeholder question. 

The guidance addresses specifically the question as to which constructs containing genes encoding botulinum neurotoxin would be subject to Select Agent regulations as outlined below and in 42 CFR § 73.3(c)(2). The regulatory provision provides:

73.3 (c) Genetic Elements, Recombinant and/or Synthetic Nucleic Acids, and Recombinant and/or Synthetic Organisms:

(2)  Recombinant and/or Synthetic nucleic acids that encode for the toxic form(s) of any of the toxins listed in paragraph (b) of this section if the nucleic acids:

(i) Can be expressed in vivo or in vitro, or

(ii)  Are in a vector or recombinant host genome and can be expressed in vivo or in vitro.

The Division of Select Agents and Toxins (DSAT) has determined the following based on the submitted questions:

Are plasmids containing full-length botulinum neurotoxin genes without a promoter for expression of the neurotoxin gene (DNA only, cannot be expressed even in a bacterial strain) subject to the select agent regulations?

No. Plasmids containing genes encoding the full-length botulinum neurotoxin without a promoter for expression of the neurotoxin genes are not regulated nucleic acids because the plasmids cannot be expressed in vitro or in vivo as outlined in § 73.3(c)(2).

Are plasmids containing full-length botulinum neurotoxin genes with a promoter for expression of the neurotoxin gene (DNA only, can be expressed only in a bacterial expression strain) subject to the select agent regulations?

Yes. Plasmids containing genes encoding the full-length botulinum neurotoxin with a promotor for expression of the neurotoxin genes are regulated nucleic acids because the plasmids can be expressed in the bacterial strain as outlined in § 73.3(c)(2).

Are plasmids containing full-length botulinum neurotoxin genes with no promoter for expression of the neurotoxin gene in a bacterial strain subject to the select agent regulations?

No. Plasmids containing genes encoding the full-length botulinum neurotoxin without a promoter for expression of the neurotoxin genes in a bacterial strain are not regulated nucleic acids because the plasmids cannot be expressed in vitro or in vivo as outlined in § 73.3(c)(2).

Are plasmids containing full-length botulinum neurotoxin genes with a promoter for expression of the neurotoxin gene in a bacterial strain subject to the select agent regulations?

Yes. Plasmids containing full-length botulinum neurotoxin genes with a promotor for expression of the neurotoxin gene in a bacterial strain are regulated nucleic acids because the plasmids can be expressed in the bacterial strain as outlined in § 73.3(c)(2).

Source: Federal Select Agent Program. Please visit SelectAgents.gov for the latest guidance.

Tags: BiosafetyBotulinum NeurotoxinBSL-3HHSSelect Agents

Related Posts

Paxlovid Has Been Free So Far. Next Year, Sticker Shock Awaits.
Health Security

Paxlovid Has Been Free So Far. Next Year, Sticker Shock Awaits.

December 7, 2022
BARDA and JPEO-CBRND Back Cepheid’s Multiplex Test for Influenza, SARS-CoV2 and RSV
Health Security

Resurgent COVID-19, Flu and Other Viruses are Pushing New Zealand’s Health System to the Limit

June 2, 2022
BugSeq Awarded BARDA DRIVe Funding to Develop Next-Gen Diagnostics for Any Respiratory RNA Virus
Health Security

BugSeq Awarded BARDA DRIVe Funding to Develop Next-Gen Diagnostics for Any Respiratory RNA Virus

May 3, 2022
U.S. Delivers Additional Vaccines and Freezer Trucks to Bangladesh for COVID Vaccination Efforts
Health Security

U.S. Delivers Additional Vaccines and Freezer Trucks to Bangladesh for COVID Vaccination Efforts

February 6, 2022
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy